Cargando…

389. Pediatric Musculoskeletal Coccidioidomycosis in Central California: Single-Center Experience

BACKGROUND: Coccidioidomycosis is an infection caused by the fungus Coccidioides (cocci), endemic to the southwest region of the United States. The burden of coccidioidomycois in Central California continues to be significant among children. Limited published literature on disseminated coccidioidomy...

Descripción completa

Detalles Bibliográficos
Autores principales: Merriott, Daniel, Gerardi, Joseph, Gholve, Purushottam, Naeem, Fouzia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253261/
http://dx.doi.org/10.1093/ofid/ofy210.400
_version_ 1783373457253203968
author Merriott, Daniel
Gerardi, Joseph
Gholve, Purushottam
Naeem, Fouzia
author_facet Merriott, Daniel
Gerardi, Joseph
Gholve, Purushottam
Naeem, Fouzia
author_sort Merriott, Daniel
collection PubMed
description BACKGROUND: Coccidioidomycosis is an infection caused by the fungus Coccidioides (cocci), endemic to the southwest region of the United States. The burden of coccidioidomycois in Central California continues to be significant among children. Limited published literature on disseminated coccidioidomycosis, including musculoskeletal coccidioidomycosis (MSKC) currently exists. METHODS: Describe the clinical course and outcomes of MSKC in a tertiary children’s hospital. RESULTS: Thirty cases were identified. Median age was 13.1 years (IQR, 5.1–14.5). Majority was male (63%), Hispanic (63%), and without comorbid conditions (70%). Common presenting features included limb swelling (60%), bony pain (50%), joint pain (43%), and fever (40%), and the majority of patients were hospitalized (90%). Pulmonary disease occurred in 57%, and 7% had meningitis. Cocci EIA antibody was positive in 63% and 90% were positive by Immunodiffusion; median serum cocci complement fixation (CF) titers were 1:128 (IQR, 64–512). Tissue/fluid culture was positive in 92%. The most commonly involved bony sites were: Craniofacial (33%), vertebrae (17%), and rib (13%). Most required surgery (77%) and 39% underwent ≥2 procedures. Twenty-six patients (86%) required ≥2 antifungal therapies with median duration of 2 years (IQR, 1.7–2.6). Overall, 83% had resolved and/or stable disease, whereas 17% experienced relapse and/or progressive disease. Additionally, older patients (≥13 years) were more likely to have two or more procedures as compared with younger patients (78% vs. 22%, P = 0.03). Trend toward higher cocci CF titers was also seen in older patients as compared with younger ones (1:256 vs. 1:64). CONCLUSION: To our knowledge, this is the largest case series of MSKC. Older patients seem to be at high risk for MSKC with more aggressive disease requiring multiple surgeries. Any musculoskeletal symptoms or high cocci CF titers should prompt early consideration and evaluation, including skeletal scintigraphy and MRI of involved area, especially in an endemic region. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253261
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62532612018-11-28 389. Pediatric Musculoskeletal Coccidioidomycosis in Central California: Single-Center Experience Merriott, Daniel Gerardi, Joseph Gholve, Purushottam Naeem, Fouzia Open Forum Infect Dis Abstracts BACKGROUND: Coccidioidomycosis is an infection caused by the fungus Coccidioides (cocci), endemic to the southwest region of the United States. The burden of coccidioidomycois in Central California continues to be significant among children. Limited published literature on disseminated coccidioidomycosis, including musculoskeletal coccidioidomycosis (MSKC) currently exists. METHODS: Describe the clinical course and outcomes of MSKC in a tertiary children’s hospital. RESULTS: Thirty cases were identified. Median age was 13.1 years (IQR, 5.1–14.5). Majority was male (63%), Hispanic (63%), and without comorbid conditions (70%). Common presenting features included limb swelling (60%), bony pain (50%), joint pain (43%), and fever (40%), and the majority of patients were hospitalized (90%). Pulmonary disease occurred in 57%, and 7% had meningitis. Cocci EIA antibody was positive in 63% and 90% were positive by Immunodiffusion; median serum cocci complement fixation (CF) titers were 1:128 (IQR, 64–512). Tissue/fluid culture was positive in 92%. The most commonly involved bony sites were: Craniofacial (33%), vertebrae (17%), and rib (13%). Most required surgery (77%) and 39% underwent ≥2 procedures. Twenty-six patients (86%) required ≥2 antifungal therapies with median duration of 2 years (IQR, 1.7–2.6). Overall, 83% had resolved and/or stable disease, whereas 17% experienced relapse and/or progressive disease. Additionally, older patients (≥13 years) were more likely to have two or more procedures as compared with younger patients (78% vs. 22%, P = 0.03). Trend toward higher cocci CF titers was also seen in older patients as compared with younger ones (1:256 vs. 1:64). CONCLUSION: To our knowledge, this is the largest case series of MSKC. Older patients seem to be at high risk for MSKC with more aggressive disease requiring multiple surgeries. Any musculoskeletal symptoms or high cocci CF titers should prompt early consideration and evaluation, including skeletal scintigraphy and MRI of involved area, especially in an endemic region. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253261/ http://dx.doi.org/10.1093/ofid/ofy210.400 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Merriott, Daniel
Gerardi, Joseph
Gholve, Purushottam
Naeem, Fouzia
389. Pediatric Musculoskeletal Coccidioidomycosis in Central California: Single-Center Experience
title 389. Pediatric Musculoskeletal Coccidioidomycosis in Central California: Single-Center Experience
title_full 389. Pediatric Musculoskeletal Coccidioidomycosis in Central California: Single-Center Experience
title_fullStr 389. Pediatric Musculoskeletal Coccidioidomycosis in Central California: Single-Center Experience
title_full_unstemmed 389. Pediatric Musculoskeletal Coccidioidomycosis in Central California: Single-Center Experience
title_short 389. Pediatric Musculoskeletal Coccidioidomycosis in Central California: Single-Center Experience
title_sort 389. pediatric musculoskeletal coccidioidomycosis in central california: single-center experience
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253261/
http://dx.doi.org/10.1093/ofid/ofy210.400
work_keys_str_mv AT merriottdaniel 389pediatricmusculoskeletalcoccidioidomycosisincentralcaliforniasinglecenterexperience
AT gerardijoseph 389pediatricmusculoskeletalcoccidioidomycosisincentralcaliforniasinglecenterexperience
AT gholvepurushottam 389pediatricmusculoskeletalcoccidioidomycosisincentralcaliforniasinglecenterexperience
AT naeemfouzia 389pediatricmusculoskeletalcoccidioidomycosisincentralcaliforniasinglecenterexperience